<?xml version='1.0' encoding='utf-8'?>
<document id="31691255"><sentence text="Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance."><entity charOffset="48-56" id="DDI-PubMed.31691255.s1.e0" text="Fentanyl" /></sentence><sentence text="Fentanyl buccal tablet (FBT), a potent opioid, was approved in Canada in 2013 for breakthrough pain in opioid-tolerant adult cancer patients"><entity charOffset="0-8" id="DDI-PubMed.31691255.s2.e0" text="Fentanyl" /><entity charOffset="39-45" id="DDI-PubMed.31691255.s2.e1" text="opioid" /><pair ddi="false" e1="DDI-PubMed.31691255.s2.e0" e2="DDI-PubMed.31691255.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31691255.s2.e0" e2="DDI-PubMed.31691255.s2.e1" /></sentence><sentence text=" Additional risk minimization measures (aRMMs), consisting of communications to patients and healthcare providers (HCPs), were implemented from November 2014 through September 2015" /><sentence text="" /><sentence text="The aim of this study was to assess the effectiveness of FBT aRMMs as measured by prescriber knowledge, understanding, and behavior regarding key safety concerns (off-label use, use in non-opioid-tolerant patients, misuse/abuse/diversion, and drug-drug interaction) and to evaluate illicit FBT use" /><sentence text="" /><sentence text="The study included three components: (1) a knowledge and understanding (KAU) survey of FBT prescribers conducted in two waves: November 2016-February 2017 and April-September 2018; (2) a retrospective prescription study of medical records of patients treated with FBT by a subgroup of prescribers from the KAU survey; and (3) Web surveillance of illicit FBT use in Canada using the search term FENTORA (May 2014-September 2018)" /><sentence text=" The aRMMs were considered effective if the lower bound of the 95% confidence interval indicated that at least 65% of respondents met or partly met the knowledge objective for each key safety concern" /><sentence text="" /><sentence text="KAU survey: Of 46 eligible HCPs, 97" /><sentence text="8% met or partly met the knowledge objective on use in breakthrough pain cancer patients, 97" /><sentence text="8% on use in opioid-tolerant patients, 89"><entity charOffset="13-19" id="DDI-PubMed.31691255.s12.e0" text="opioid" /></sentence><sentence text="1% on dose and titration, 100% on abuse/addiction, and 58" /><sentence text="7% on drug-drug interaction" /><sentence text=" Retrospective prescription study: Of 22 FBT-treated patients identified from 14 HCPs, 45" /><sentence text="5% had cancer, 50" /><sentence text="0% recorded a breakthrough pain indication, and 36" /><sentence text="4% reported opioid tolerance; however, only 13"><entity charOffset="12-18" id="DDI-PubMed.31691255.s18.e0" text="opioid" /></sentence><sentence text="6% of patients were prescribed FBT according to the approved indication" /><sentence text=" Web surveillance: Of 932 FBT posts in Canada, only 40 (4" /><sentence text="3%) mentioned illicit use" /><sentence text="" /><sentence text="The aRMMs as measured by the prescriber KAU were effective for most key safety messages; however, not all key messages of the aRMMs were stringently followed in routine practice" /><sentence text="" /></document>